Latest Kaiser Health News Stories
California lawmakers are proposing ambitious health care ideas, from creating a state generic drug label to banning the sale of flavored e-cigarette products. Even though Democrats control state government, they’re likely to face pushback from powerful health care industry groups like hospitals.
The impact of the Trump administration’s health policies is not as clear-cut as the president’s reelection campaign suggests.
A federal appeals court in New Orleans has agreed with a lower court that a key piece of the Affordable Care Act is unconstitutional. But it is sending the case back to the lower-court judge to decide how much of the rest of the law can stand. Also, Congress is leaving town after finishing work on a major spending bill that includes many changes to health policy. Margot Sanger-Katz of The New York Times, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more.
The administration’s proposed rule to allow states to bring in prescription medications isn’t expected to provide immediate relief.
KHN correspondent Shefali Luthra was among the guests on the podcast “Today, Explained” to talk about PrEP.
KHN’s Emmarie Huetteman appeared on PBS NewsHour to discuss efforts on Capitol Hill to curb the cost of prescription drugs.
The House passed legislation that would give federal workers 12 weeks of paid parental leave. The measure appears headed for passage in the Senate, and President Donald Trump has promised to sign the measure into law. Meanwhile, House and Senate lawmakers have a tentative deal on surprise medical bills, but don’t count on a compromise just yet. Joanne Kenen of Politico, Kimberly Leonard of the Washington Examiner and Emmarie Huetteman of Kaiser Health News join guest host Mary Agnes Carey of KHN to discuss this and more. And for “extra credit,” the panelists offer their favorite health stories of the week they think you should read, too.
The annual accounting of national health spending is out. And the 2018 health bill for the U.S. was $3.6 trillion, consuming nearly a fifth of the nation’s economy. Meanwhile, Congress is nearing the end of the year without having finished either its annual spending bills or several other high-priority health items. Kimberly Leonard of the Washington Examiner, Joanne Kenen of Politico and Mary Agnes Carey of Kaiser Health News join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Markian Hawryluk about the latest KHN-NPR “Bill of the Month.”
Open enrollment for the Affordable Care Act’s marketplace plans is halfway over and, so far, the number of people signing up is down, but not dramatically. Meanwhile, Congress and President Donald Trump can’t seem to agree on what to do about teen vaping, drug prices or “surprise” medical bills. And Democrats lurch to the left on abortion. Paige Winfield Cunningham of The Washington Post, Kimberly Leonard of the Washington Examiner and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news.
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
KHN’s Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.